More American teenagers now use the weight-loss drug Wegovy, as doctors and families grow more comfortable with the treatment ...

Also: A Medicare crisis and doctors’ concerns with Kennedy’s new coronavirus vaccine policy.

A new study brings into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease.

In an emailed statement to CBS News Monday, a spokesperson for Novo Nordisk, the maker of Wegovy and Ozempic, said both Wegovy and Zepbound have ... and known heart disease backed by real-world ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50 per cent more weight than those using rival Novo Nordisk's Wegovy.

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

Many folks in NC can’t access Ozempic due to limited insurance coverage. But policy changes and falling prices may expand ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing cancer ...

Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the ...

But the Globe analysis found that patients taking drugs such as Wegovy, Ozempic, Mounjaro, and Zepbound are disproportionately ... such as cardiovascular disease or high blood pressure.